[Description]:
Ketoprofen (RP-19583) lysinate is a non-steroidal anti-inflammatory agent. Ketoprofen lysinate can inhibit the activity of cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity[1][2][3].
[Related Catalog]:
[Target]
COX-1:2 nM (IC50)
COX-2:26 nM (IC50)
[In Vitro]
Ketoprofen lysinate inhibits COX in LPS-stimulated monocytes isolated from human blood, with IC50 values of 2 nM (COX-1) and 26 nM (COX-2)[1]. Ketoprofen lysinate (2.5 mg /mL, 3-24h) decreases the mRNA level of immune factors (TNFα, IL-8, SAA and COX-2) and PTGES in LPS-stimulated bovine mammary epithelial cells[3]. RT-PCR[3] Cell Line: LPS (0.2 μg/mL)-stimulated bovine mammary epithelial cells Concentration: 2.5 mg /mL Incubation Time: 3, 6, 24 h Result: Decreased the mRNA level of TNFα, IL-8, SAA, COX-2 and PTGES.
[In Vivo]
Ketoprofen lysinate (Oral administration, 10 mg/kg, three times a week for 10 weeks, HFD-induced obese C57BL/6 mice) decreases in relative body weight (15.41%), the iWAT mass (approximately 41%), and leptin (58.68%) and resistin (12.88%)[2]. Ketoprofen lysinate (50 mg/kg, LPS-treated dairy cows) lowers the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk induced by LPS[3]. Animal Model: HFD-induced obese C57BL/6 mice[2] Dosage: 10 mg/kg Administration: Oral administration, three times a week for 10 weeks Result: Decreased in relative body weight, the iWAT mass, and the level of leptin and resistin. Animal Model: LPS (0.2 μg/mL)-treated dairy cows [3] Dosage: 50 mg/kg Administration: Injection (Milk samples were taken every 30 min until 6 and 9 h) Result: Lowered the increase of somatic cell count (SCC), serum albumin (SA), IgG and lactate dehydrogenase (LDH) activity in milk.
[References]